Sage Therapeutics (SAGE) : The money flow analysis of Sage Therapeutics (SAGE) indicates a $0.44 million of outflow was on downticks, whereas, the investors on Friday gobbled up stocks worth $0.65 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.49 and so was the total money flow at $0.21 million. The bulls lapped up $0 million worth of block trades on upticks. The money flow was $0 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Sage Therapeutics (SAGE), pushing it down by -1.06% for the day. The stock slid $0.39 and traded at $36.57 during the day. Nonetheless, the stock is -5.19% over the previous weeks close.
The company Insiders own 5.6% of Sage Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -10.76% . Institutional Investors own 93.93% of Sage Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -17.56%.
In a related news, Robichaud Albert, (Chief Scientific Officer) of Sage Therapeutics, Inc., unloaded 22,000 shares at an average price of $40 on July 12, 2016. The total amount of the transaction was worth $880,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Sage Therapeutics (NASDAQ:SAGE): stock was range-bound between the intraday low of $36.01 and the intraday high of $37.09 after having opened at $37.03 on Fridays session. The stock finally closed in the red at $37.03, a loss of -1.33%. The stock remained in the red for the whole trading day. The total traded volume was 269,110 shares. The stock failed to cross $37.09 in Fridays trading. The stocks closing price on Thursday was $36.96.
Sage Therapeutics (SAGE) : During the past 4 weeks, traders have been relatively bearish on Sage Therapeutics (SAGE), hence the stock is down -17% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.92% relative to the S&P 500. The 4-week change in the price of the stock is -17.11% and the stock has fallen -5.44% in the past 1 week.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.